Live feed/
Filings
/
SCHEDULE
/
0001104659-25-006733
Stake: 4.90%
Shares: 939,238
CUSIP: 74907L300
Class: Ordinary Shares, no par value per share (represented by American Depositary Shares)
Item 4 — Purpose of Transaction
The Ordinary Shares reported herein as beneficially owned by the Reporting Person were acquired by the Reporting Person for investment purposes. As a result of the exercise of pre-funded warrants, Series F Warrants and Series G Warrants by other investors in the Company's December 2024 offering, the Company's outstanding Ordinary Shares (represented by ADSs) as of January 27, 2025 increased to 18,485,830. As a result of such exercises, the Reporting Person's beneficial ownership decreased to below 5% of the Company's outstanding Ordinary Shares (represented by ADSs).
Cross-References
Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
4 13D/G filings on this issuer
3 other filings besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest · settle 2026-07-15
DTC 3.91
156,280 shares short · -40.3% vs prior
Post-Filing Returns · since 2025-01-27 on QNRX
Anchor price 4.80 on closest trading day on/after 2025-01-27. Source: Yahoo Finance daily adj_close (split + dividend adjusted).
Other 13D/G Filings on Quoin Pharmaceuticals, Ltd.
| Filed | Form | Filer | Stake | Shares | |
|---|
| 2025-01-28 |
SCHEDULE |
Myers Michael |
4.90% |
939,230 |
view → |
| 2020-04-22 |
SC |
Yarkoni Shai |
— |
— |
view → |
| 2019-02-20 |
SC |
Yarkoni Shai |
— |
— |
view → |
Want this depth on every filing the moment it hits SEC EDGAR?
Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.
See pricing →